恶性胸膜间皮瘤(MPM)诊治共识(2022,杭州)

Consensus on Diagnosis and Treatment of Malignant Pleural Mesothelioma (MPM) (2022, Hangzhou)

恶性胸膜间皮瘤(malignant pleural mesothelioma,MPM)是一种发病率较低的恶性肿瘤,近20年来发病率呈增长趋势。恶性胸膜间皮瘤高风险人群及患者的早诊早治对恶性胸膜间皮瘤的治疗至关重要。制定符合中国国情的恶性胸膜间皮瘤的诊治共识指南,将促进中国恶性胸膜间皮瘤早期诊断的同质性和规范性。《恶性胸膜间皮瘤(MPM)诊治共识(2022,杭州)》由中国抗癌协会肺癌专业委员会发起,联合多学科专家,根据《世界卫生组织指南制定手册》的原则和方法,整合近年来国内外在恶性胸膜间皮瘤诊断与治疗方面的新进展,同时结合恶性胸膜间皮瘤临床实践经验。针对恶性胸膜间皮瘤的流行病学、病理学、辅助检查、手术、放疗、内科治疗、电场治疗、姑息支持治疗等关键问题给出了详细的循证推荐。旨在规范恶性胸膜间皮瘤筛查与早诊早治实践,进一步提升中国恶性胸膜间皮瘤患者的生存率。

Malignant pleural mesothelioma(MPM) is a kind of malignant tumor with an increasing incidence in the past 20 years. Early diagnosis and precise treatment of patients with high risk is very important for the therapy of MPM. The consensus on diagnosis and treatment of MPM(2022,Hangzhou) initiated by Lung Cancer Committee of Chinese Anti-Cancer Associa-tion with the assistant of multi-disciplinary experts in line with China’s national conditions will promote the homogeneity and standardization of treatment of MPM in Chinese people. According to WHO Handbook for Guideline Development, the consensus integrated the progress in diagnosis and treatment of MPM at home and abroad in recent years. Detailed evidence-based recommendations for the epidemiology, pathology, auxiliary examination, surgery, radiotherapy, medical treatment, electric field therapy, palliative care and other key issues of MPM were presented. The standard of screening and early diagnosis and treatment of MPM were fundamental for improving the survival rate generally.